View Future GrowthPsyence Group 過去の業績過去 基準チェック /06Psyence Groupの収益は年平均-11.5%で減少しているが、Biotechs業界はgrowingで36.2%年平均の収益となった。主要情報-11.52%収益成長率4.23%EPS成長率Biotechs 業界の成長51.09%収益成長率n/a株主資本利益率-1,898.58%ネット・マージンn/a前回の決算情報30 Sep 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.1m free cash flow). Shares are highly illiquid. Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.88m market cap, or US$1.34m).お知らせ • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$2.23m market cap, or US$1.64m).お知らせ • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.New Risk • Jul 31New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$12m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.9m free cash flow). Share price has been highly volatile over the past 3 months (55% average weekly change). Negative equity (-CA$12m). Revenue is less than US$1m. Market cap is less than US$10m (CA$3.50m market cap, or US$2.54m). Minor Risk Shareholders have been diluted in the past year (6.3% increase in shares outstanding).お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.お知らせ • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$4.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.2m free cash flow). Share price has been highly volatile over the past 3 months (38% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.12m market cap, or US$3.04m). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding).お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.New Risk • Nov 19New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$241k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (80% average weekly change). Negative equity (-CA$241k). Revenue has declined by 100% over the past year. Revenue is less than US$1m. Market cap is less than US$10m (CA$8.25m market cap, or US$6.01m). Minor Risk Shareholders have been diluted in the past year (44% increase in shares outstanding).お知らせ • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.Board Change • Oct 10Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Co-Founder & Executive Chairman Jody Aufrichtig is the most experienced director on the board, commencing their role in 2021. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Aug 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$11.9m (US$8.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.9m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$11.9m market cap, or US$8.75m).New Risk • Jul 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.9m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$14.5m market cap, or US$10.9m).お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.お知らせ • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.お知らせ • Nov 30Psyence Group Inc. Announces Resignation of Gavin Basserabie from BoardPsyence Group Inc. announced that Gavin Basserabie has tendered his resignation from the board with immediate effect, however as a founder, he retains a strong interest in the Company. The board of directors of the Company consists of Jody Aufrichtig, Dr. Neil Maresky, Alan Friedman and Marvin Singer.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 11Psyence Group Inc. announced that it expects to receive CAD 1.22 million in fundingPsyence Group Inc. announced a non-brokered private placement of CAD 1.22 million from a consortium led by Brandon Kerzner on November 10, 2022. The company has signed subscription agreements in the transaction. The company is seeking to raise up to CAD 3 million and may upsize the financing at its discretion. The transaction is subject to the approval of the CSE and the securities will be subject to a four month hold period under securities laws.お知らせ • Sep 20Psyence Group Inc. Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory AgencyPsyence Group Inc. announced that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent regulatory body to Canada’s Health Canada and the US’s FDA. The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis. Psyence has partnered with a psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom. Psyence aims to commence this study by the end of the year.Board Change • Aug 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 01Psyence Group Inc. Taps Another Pharma Exec to Drive Its Clinical ProgramPsyence Group Inc. announced the appointment of Dr. Clive Ward-Able as the Medical Director of Psyence Group, effective immediately. Dr. Ward-Able joins the existing medical team in Toronto and also assumes the roles of Head of Research & Development (R&D) and Early Commercialization. Dr. Ward-Able has degrees in both Pharmacy and Medicine and has over thirty years’ experience in the pharmaceutical industry, within R&D, medical affairs, marketing and sales. The majority of his experience is in the medical aspects of the commercialization of a pharmaceutical product. He has been involved with the launch of over 16 products in multiple therapeutic areas. He also has direct involvement with the design and conduct of clinical trials. Dr. Ward-Able will oversee the execution of Psyence’s first clinical trial to the standards. Psyence is designing market-leading clinical trials using natural psilocybin in the field of palliative care, which will initially be conducted in the United Kingdom. The clinical trial programme is focused on assessing the safety and efficacy of psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to an incurable cancer diagnosis versus psychotherapy alone.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 08Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production FacilityPsyence Group Inc. announced that its ISO22000 graded Psilocybin production facility has officially received International Organization for Standardization(ISO) 22000:2018 certification, awarded through the British Standards Institute (BSI). ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems. Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021. The facility was designed and constructed to ISO 14644-1 cleanroom specifications and engineering design principles. This design allows various parts of the process to comply with the Good Manufacturing Practice (GMP) Standards required for product safety and quality in order to meet the certification needs of the BSI. The facility is equipped with validated and calibrated specialised equipment to ensure optimum growing conditions and efficient harvesting and packaging. With this certification, Psyence is one step closer to producing pharmaceutical grade product for human clinical trials, including Psyence’s clinical trial in the field of palliative care and clinical trials run by research organisations.お知らせ • Dec 03Psyence Group Inc. announced that it expects to receive CAD 2 million in fundingPsyence Group Inc. announced a non-brokered private placement of unsecured convertible promissory notes for the gross proceeds of CAD 2,000,000 on December 2, 2021. The notes are convertible at the option of the holder at any time and will be automatically converted upon the occurrence of certain events at a 20% discount to the market price of the company’s common shares at the time of conversion, subject to a minimum conversion price of CAD 0.25 and a maximum conversion price of CAD 0.40. The notes will mature in 24 months from their date of issuance and bear interest at a rate of 8% per annum.Executive Departure • Mar 10Director has left the companyOn the 4th of March, Ryan Roebuck's tenure in the role of Director ended. We don't have any record of a personal shareholding under Ryan's name. Ryan is the only executive to leave the company over the last 12 months.お知らせ • Mar 07+ 2 more updatesPsyence Group Announces Partnership with Base Pair HealthPsyence Group Inc. announced that it has entered into a Service Level Agreement with Base Pair Global Pte. Ltd. trading as Base Pair Health (BPH). BPH develops advanced nutritional and health products for global clients, with a strong focus on organic and naturally occurring ingredients. Psyence’s world-class medical and scientific team are focused on innovative research and clinical trials in order to develop class-leading psychedelic medicines for the treatment of psychological trauma and its mental health consequences. BPH provides advisory services for new health product design and implementation. BPH develops advanced nutritional products, ranging from supplements, minerals, herbal remedies, vitamins and specialty products, with a strong focus on organic ingredients.お知らせ • Mar 06Psyence Group Inc. Announces Board ChangesPsyence Group Inc. announced the appointment of Alan Friedman to the Board of Directors. Alan Friedman is principal of Bayline Capital Partners. He has been associated with the North American public markets for two decades and has a depth of experience in representing, advising and assisting Canadian and global companies in acquiring assets, accessing capital, advising on mergers and acquisitions and navigating going public processes onto Canadian, US and UK stock exchanges with accompanying equity capital raisings. The Company further announced that Ryan Roebuck has resigned from the Board effective immediately.お知らせ • Feb 12Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at its Commercially Licensed FacilityPsyence Group Inc. announced that it has concluded its first cultivation and harvest cycle of natural medical psilocybin mushrooms. The mushrooms were grown, harvested, processed, and packed at its premium production facility in Lesotho which has been designed and built to the highest international standards. The facility, which is based in Lesotho (Southern Africa), has been designed and constructed to International Organization for Standardization (ISO) 14644-1 Cleanroom specifications and engineering design principles. This design allows various parts of the process to comply with the Good Manufacturing Practice ("GMP") Standards required for product safety and quality to meet the certification needs of The British Standards Institute ("BSI"). The facility is registered with the US Food and Drug Administration ("US-FDA") and is equipped with validated and calibrated specialised equipment to ensure optimum growing conditions and efficient harvesting and packaging. Through process, equipment and facility validations, Psyence ensures a consistent end product in terms of safety and quality. The facility design allows for rapid expansion with minimum interference to operations. The first harvest is serving as an R&D batch. It is being used to inform product characterization as well as to test transport routes to global licensed research and medical customers in legal jurisdictions. Following the success of the first harvest, three more batches will be cultivated and harvested in order to validate all of the processes as roadmap to attaining BSI certification. Cultivation of the second batch is already underway; the cultivation and harvesting process, from spore inoculation to vacuum packing and storing takes approximately 10 weeks to complete and can be done on a continual basis. Following the conclusion of three successful and approved validation batches the processes will be audited and BSI certification will be concluded.収支内訳Psyence Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史CNSX:PSYG 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費30 Sep 250-123030 Jun 250-134131 Mar 25005031 Dec 240-285130 Sep 240-245130 Jun 240-264031 Mar 240-284231 Dec 230-53330 Sep 230-73330 Jun 230-74331 Mar 230-64231 Dec 220-44130 Sep 220-44030 Jun 220-54031 Mar 220-54031 Dec 210-155030 Sep 210-156030 Jun 210-1550質の高い収益: PSYGは現在利益が出ていません。利益率の向上: PSYGは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PSYGは利益が出ておらず、過去 5 年間で損失は年間11.5%の割合で増加しています。成長の加速: PSYGの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PSYGは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 31.5% ) と比較することは困難です。株主資本利益率高いROE: PSYGは現在利益が出ていないため、自己資本利益率 ( -1898.58% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/20 21:13終値2025/11/24 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psyence Group Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ryan HamptonHannam & Partners (Advisory) LLP
お知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.
New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.1m free cash flow). Shares are highly illiquid. Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.88m market cap, or US$1.34m).
お知らせ • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.
New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$2.23m market cap, or US$1.64m).
お知らせ • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.
お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.
New Risk • Jul 31New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$12m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.9m free cash flow). Share price has been highly volatile over the past 3 months (55% average weekly change). Negative equity (-CA$12m). Revenue is less than US$1m. Market cap is less than US$10m (CA$3.50m market cap, or US$2.54m). Minor Risk Shareholders have been diluted in the past year (6.3% increase in shares outstanding).
お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.
お知らせ • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$4.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.2m free cash flow). Share price has been highly volatile over the past 3 months (38% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.12m market cap, or US$3.04m). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding).
お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.
New Risk • Nov 19New major risk - Negative shareholders equityThe company has negative equity. Total equity: -CA$241k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (80% average weekly change). Negative equity (-CA$241k). Revenue has declined by 100% over the past year. Revenue is less than US$1m. Market cap is less than US$10m (CA$8.25m market cap, or US$6.01m). Minor Risk Shareholders have been diluted in the past year (44% increase in shares outstanding).
お知らせ • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.
Board Change • Oct 10Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Co-Founder & Executive Chairman Jody Aufrichtig is the most experienced director on the board, commencing their role in 2021. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Aug 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$11.9m (US$8.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.9m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$11.9m market cap, or US$8.75m).
New Risk • Jul 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.9m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$14.5m market cap, or US$10.9m).
お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.
お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.
お知らせ • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.
お知らせ • Nov 30Psyence Group Inc. Announces Resignation of Gavin Basserabie from BoardPsyence Group Inc. announced that Gavin Basserabie has tendered his resignation from the board with immediate effect, however as a founder, he retains a strong interest in the Company. The board of directors of the Company consists of Jody Aufrichtig, Dr. Neil Maresky, Alan Friedman and Marvin Singer.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 11Psyence Group Inc. announced that it expects to receive CAD 1.22 million in fundingPsyence Group Inc. announced a non-brokered private placement of CAD 1.22 million from a consortium led by Brandon Kerzner on November 10, 2022. The company has signed subscription agreements in the transaction. The company is seeking to raise up to CAD 3 million and may upsize the financing at its discretion. The transaction is subject to the approval of the CSE and the securities will be subject to a four month hold period under securities laws.
お知らせ • Sep 20Psyence Group Inc. Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory AgencyPsyence Group Inc. announced that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent regulatory body to Canada’s Health Canada and the US’s FDA. The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis. Psyence has partnered with a psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom. Psyence aims to commence this study by the end of the year.
Board Change • Aug 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 01Psyence Group Inc. Taps Another Pharma Exec to Drive Its Clinical ProgramPsyence Group Inc. announced the appointment of Dr. Clive Ward-Able as the Medical Director of Psyence Group, effective immediately. Dr. Ward-Able joins the existing medical team in Toronto and also assumes the roles of Head of Research & Development (R&D) and Early Commercialization. Dr. Ward-Able has degrees in both Pharmacy and Medicine and has over thirty years’ experience in the pharmaceutical industry, within R&D, medical affairs, marketing and sales. The majority of his experience is in the medical aspects of the commercialization of a pharmaceutical product. He has been involved with the launch of over 16 products in multiple therapeutic areas. He also has direct involvement with the design and conduct of clinical trials. Dr. Ward-Able will oversee the execution of Psyence’s first clinical trial to the standards. Psyence is designing market-leading clinical trials using natural psilocybin in the field of palliative care, which will initially be conducted in the United Kingdom. The clinical trial programme is focused on assessing the safety and efficacy of psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to an incurable cancer diagnosis versus psychotherapy alone.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marvin Singer was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 08Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production FacilityPsyence Group Inc. announced that its ISO22000 graded Psilocybin production facility has officially received International Organization for Standardization(ISO) 22000:2018 certification, awarded through the British Standards Institute (BSI). ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems. Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021. The facility was designed and constructed to ISO 14644-1 cleanroom specifications and engineering design principles. This design allows various parts of the process to comply with the Good Manufacturing Practice (GMP) Standards required for product safety and quality in order to meet the certification needs of the BSI. The facility is equipped with validated and calibrated specialised equipment to ensure optimum growing conditions and efficient harvesting and packaging. With this certification, Psyence is one step closer to producing pharmaceutical grade product for human clinical trials, including Psyence’s clinical trial in the field of palliative care and clinical trials run by research organisations.
お知らせ • Dec 03Psyence Group Inc. announced that it expects to receive CAD 2 million in fundingPsyence Group Inc. announced a non-brokered private placement of unsecured convertible promissory notes for the gross proceeds of CAD 2,000,000 on December 2, 2021. The notes are convertible at the option of the holder at any time and will be automatically converted upon the occurrence of certain events at a 20% discount to the market price of the company’s common shares at the time of conversion, subject to a minimum conversion price of CAD 0.25 and a maximum conversion price of CAD 0.40. The notes will mature in 24 months from their date of issuance and bear interest at a rate of 8% per annum.
Executive Departure • Mar 10Director has left the companyOn the 4th of March, Ryan Roebuck's tenure in the role of Director ended. We don't have any record of a personal shareholding under Ryan's name. Ryan is the only executive to leave the company over the last 12 months.
お知らせ • Mar 07+ 2 more updatesPsyence Group Announces Partnership with Base Pair HealthPsyence Group Inc. announced that it has entered into a Service Level Agreement with Base Pair Global Pte. Ltd. trading as Base Pair Health (BPH). BPH develops advanced nutritional and health products for global clients, with a strong focus on organic and naturally occurring ingredients. Psyence’s world-class medical and scientific team are focused on innovative research and clinical trials in order to develop class-leading psychedelic medicines for the treatment of psychological trauma and its mental health consequences. BPH provides advisory services for new health product design and implementation. BPH develops advanced nutritional products, ranging from supplements, minerals, herbal remedies, vitamins and specialty products, with a strong focus on organic ingredients.
お知らせ • Mar 06Psyence Group Inc. Announces Board ChangesPsyence Group Inc. announced the appointment of Alan Friedman to the Board of Directors. Alan Friedman is principal of Bayline Capital Partners. He has been associated with the North American public markets for two decades and has a depth of experience in representing, advising and assisting Canadian and global companies in acquiring assets, accessing capital, advising on mergers and acquisitions and navigating going public processes onto Canadian, US and UK stock exchanges with accompanying equity capital raisings. The Company further announced that Ryan Roebuck has resigned from the Board effective immediately.
お知らせ • Feb 12Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at its Commercially Licensed FacilityPsyence Group Inc. announced that it has concluded its first cultivation and harvest cycle of natural medical psilocybin mushrooms. The mushrooms were grown, harvested, processed, and packed at its premium production facility in Lesotho which has been designed and built to the highest international standards. The facility, which is based in Lesotho (Southern Africa), has been designed and constructed to International Organization for Standardization (ISO) 14644-1 Cleanroom specifications and engineering design principles. This design allows various parts of the process to comply with the Good Manufacturing Practice ("GMP") Standards required for product safety and quality to meet the certification needs of The British Standards Institute ("BSI"). The facility is registered with the US Food and Drug Administration ("US-FDA") and is equipped with validated and calibrated specialised equipment to ensure optimum growing conditions and efficient harvesting and packaging. Through process, equipment and facility validations, Psyence ensures a consistent end product in terms of safety and quality. The facility design allows for rapid expansion with minimum interference to operations. The first harvest is serving as an R&D batch. It is being used to inform product characterization as well as to test transport routes to global licensed research and medical customers in legal jurisdictions. Following the success of the first harvest, three more batches will be cultivated and harvested in order to validate all of the processes as roadmap to attaining BSI certification. Cultivation of the second batch is already underway; the cultivation and harvesting process, from spore inoculation to vacuum packing and storing takes approximately 10 weeks to complete and can be done on a continual basis. Following the conclusion of three successful and approved validation batches the processes will be audited and BSI certification will be concluded.